SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending due to the commercial launch of TONMYA, a first-in-class fibromyalgia treatment, sparking discussions about its market potential and insurance coverage. While some express concerns over past dilutions and future profitability, others highlight the company's cash runway and potential for a squeeze. The community is closely watching for sales data and confirmation of distribution milestones as key catalysts for price movement.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending due to recent earnings report indicating a 50% YoY revenue increase and record customer growth, although margins were pressured by higher delivery expenses. Community discussion revolves around the impressive revenue numbers and store expansion, with some expressing concern over margin decline and a lack of updates regarding a potential US relisting. Overall, while growth is undeniable, the sustainability of margins and potential catalysts like relisting are key talking points.

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Zymeworks Inc

ZYME is trending following positive Phase 3 trial results for their cancer treatment Ziihera, developed in partnership with Jazz Pharmaceuticals. The community is discussing the potential impact on HER2-positive cancers and the financial implications for both ZYME and Jazz. Some traders caution about low trading volume and the potential risks of getting in now.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending after Berkshire Hathaway disclosed a $4.3 billion stake, fueling optimism and driving shares up. The community is discussing whether this move signals a broader shift in Warren Buffett's investment strategy towards tech and AI, while others debate the valuation and potential for further gains. This news coincides with Alphabet's ongoing investments in data centers to support cloud and AI initiatives.

Grindr, Inc. engages in the operation of a social media network application for the gay, bi, trans, queer, and other members of the LGBTQ+ community. The company was founded in 2009 and is headquartered in West Hollywood, CA.

Grindr Inc - Ordinary Shares - Class A

Grindr Inc

Grindr is trending amid buyout speculation, with community members debating the likelihood of a deal and potential premium. Discussions also involve insider selling and its impact on a possible acquisition. Despite the uncertainty, some believe GRND is undervalued, citing strong earnings and analyst price targets.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet (STRK) is trending due to a surge in staking and BTCFi incentives, with the community noting a strong weekly breakout and increased bullish sentiment. Discussions highlight the potential of Starknet's technology, particularly its zero-knowledge proof system, and its growing ecosystem, with some viewing it as a key player in the future of decentralized finance. Comparisons to Zcash ($ZEC) are also circulating, emphasizing the privacy aspects of Starknet.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium ($SGML) is trending amid discussions around lithium prices, production capacity, and potential takeover scenarios. Community members are analyzing the impact of fluctuating lithium prices on the company's future earnings and debating whether recent price movements signal a potential sector recovery, while also noting insider buying activity. Some traders discuss technical indicators and potential short squeezes, while cautioning of continued volatility given recent price action.

Meme coin community on Aurora focuses on promoting the NEAR eco and fostering camaraderie and promotions of member's content creation.

Shitzu

Shitzu is trending heavily as traders actively discuss the cryptocurrency. Increased social media mentions suggest growing interest and speculative trading, though the specific catalyst for the surge in attention remains unclear. The community is focused on the potential of this relatively new and volatile cryptocurrency.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending due to positive developments in AI and robotics, including the unveiling of its 'Iron' humanoid robot, and expansion into new European markets. Community discussions revolve around the company's potential to surpass Tesla in robotics and its attractive valuation relative to its growth and innovation. Upcoming earnings are also a key point of interest, with investors anticipating strong results.

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

Wasatch Pharmaceutical Inc

Wasatch Pharmaceutical ($WSHP) is trending due to its recent direct listing, with the community actively discussing its volatile price action and potential trading opportunities. Some traders are highlighting the stock's significant move post-listing, while others are cautious, pointing to potential risks. Chatter suggests possible upcoming news related to the company.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter picked up on Cel-Sci Corporation on Wednesday as investors awaited a key decision from the Saudi Food and Drug Authority (SFDA) on the company’s application for Breakthrough Medicine Designation for its cancer immunotherapy, Multikine.&nbsp;The ruling could come soon, as the SFDA’s 60-day review window is nearing its close.In August, Cel-Sci signed a Memorandum of Understanding with a leading Saudi pharmaceutical company, which submitted the application to the SFDA. A final commercialization agreement between the two partners is expected in the third quarter of 2025. The Saudi partner is also expected to facilitate reimbursement and accelerate Multikine’s sale and patient access in the Kingdom.The move has drawn growing interest from Saudi investment funds looking to back Multikine and Cel-Sci’s expansion across the Middle East and North Africa region.Multikine is designed to strengthen a patient’s immune system before surgery for newly diagnosed, untreated head and neck cancer. In a global Phase 3 study, the largest of its kind, the therapy improved five-year survival rates to 73% from 45% among patients receiving standard care alone, cutting the risk of death by half.If approved, Multikine would qualify for accelerated patient access and reimbursement under Saudi Arabia’s Breakthrough Medicine Program, which aims to fast-track treatments for serious or life-threatening diseases that meet unmet medical needs.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘high’ message volume.One user noted that Cel-Sci’s April update indicated the company was encouraged to seek conditional approval under the Breakthrough Therapy Designation. The filing was made around mid-August, suggesting a decision could be imminent.<stembedurl>https://stocktwits.com/NavyPatrol657/message/632324726</stembedurl>Another user expressed anticipation for an update from CEO Geert Kersten, while a third observed that the stock might remain subdued until the SFDA announcement.<stembedurl>https://stocktwits.com/prophet777/message/632356422</stembedurl><stembedurl>https://stocktwits.com/NoobFriendly/message/632216212</stembedurl><a href="https://stocktwits.com/symbol/CVM">CEL-SCI Corporation’s stock</a> has declined 18% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CEL-SCI Corporation’s stock (CVM) has declined 18% so far in 2025.| Image source: Getty Images

Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine

Multikine is a cancer immunotherapy, which has significantly improved survival in head and neck cancer patients during global Phase 3 trials.

Equity

CEL-SCI Corporation (CVM) on Friday announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical companies for a partnership that spans regulatory and commercial activities for Multikine in the Kingdom of Saudi Arabia.<a href="https://stocktwits.com/symbol/CVM">CEL-SCI</a>’s shares were trading 33% higher at the time of writing.The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250711051288/en/CEL-SCI-to-Sign-Partnership-Agreement-With-Leading-Saudi-Arabian-Pharma-Company-for-Multikine-in-the-Treatment-of-Head-Neck-Cancer">said</a>. The partner will then file a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA).Multikine is a cancer drug administered before surgery as a treatment for newly diagnosed and previously untreated head and neck cancer.If granted Breakthrough Medicine Designation, Multikine would immediately become available for patient access, reimbursement, or sale in Saudi Arabia. CEL-SCI said that it believes Multikine meets all requirements for Breakthrough Medicine Designation as published by the SFDA and is now developing a comprehensive commercialization plan with its Saudi pharma partner.In a study spanning 20 countries, Multikine increased the 5-year survival rate of the target patient population to 73% versus 45% in patients treated with standard of care alone. The 5-year risk of death was halved from 55% to 27%.The drug, given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.CEL-SCI also said on Friday that several Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market.On Stocktwits, retail sentiment around CVM jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_11_59_25_AM_png_2f84b0779d.webp" alt="CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits" width="625" height="63"><figcaption>CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>CVM stock is down by 58% this year and by over 86% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-reportedly-stands-firm-on-eu-ad-model/ch8cirOR5Zw">Meta Reportedly Stands Firm On EU Ad Model Amid Looming Regulatory Penalties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled

The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, CEL-SCI said.

Shares of Cel-Sci Corp ($CVM) slipped in the after-hours trading session on Friday following the company’s announcement of a share offering, with retail sentiment staying neutral. The purchase price of the offering, for its common stock par value of $0.01 per share, wasn’t immediately known. The last reported sale price of its stock was $0.70 per share. According to the company’s filing with the SEC, it is offering potential purchasers, along with related parties who own more than 4.99% of its outstanding common stock immediately following the consummation of this offering, the opportunity to purchase pre-funded warrants exercisable at an exercise price of $0.01 per share.The purchase price of each pre-funded warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01, the statement said.The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full, the statement added. For each warrant, the number of shares of common stock on offer will be decreased on a one-for-one basis.&nbsp; Retail sentiment on Stocktwits has been ‘neutral’ compared to a week ago. Message volumes have been in the normal range. &nbsp;<figure class="image"><img style="aspect-ratio:1256/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_30_at_11_21_09_AM_2d60d70bed.png" alt="Screenshot 2024-12-30 at 11.21.09 AM.png" width="1256" height="302"><figcaption>CVM sentiment meter and message volumes on Dec 29</figcaption></figure><stembedurl>https://stocktwits.com/phoenix31415/message/598120019</stembedurl>A ‘bearish’ commenter was not convinced on the terms.<stembedurl>https://stocktwits.com/ThaDreadPirate/message/598079934</stembedurl>The company has engaged ThinkEquity as the placement agent in connection with this offering.Cel-Sci develops immunotherapy products for the treatment of cancer and infectious diseases.Cel-Sci stock is down 77% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cel-Sci Stock Slips After Public Offering: Retail's Neutral

The purchase price of each pre-funded Warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$6.50
Prev Close	$6.63
Open	$6.55
Dividend Yield	0.00%
50-Day Moving Average	$8.83
Beta	1.04
Avg. Volume	100,379.13
PE Ratio	-0.67

52-Week High	$32.70
52-Week Low	$1.98
Market Capitalization	$52.92M
EPS (Annual)	-$14.94
Price to Book	5.01
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

CVM
Cel-Sci Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CVM News

CVMCel-Sci Corp